Published in World J Gastroenterol on October 14, 2015
Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form. Int J Mol Sci (2016) 0.81
Geographic integration of hepatitis C virus: A global threat. World J Virol (2016) 0.76
Tumour virus epidemiology. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Hepatitis C treatment: where are we now? Int J Gen Med (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (2011) 6.21
Treatment of hepatitis C: a systematic review. JAMA (2014) 4.99
Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol (2014) 4.82
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol (2007) 4.09
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol (2013) 4.05
Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (2014) 3.95
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet (2013) 3.65
Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis (2000) 3.01
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol (2007) 2.55
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther (2014) 2.44
HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill (2011) 2.42
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect (2013) 2.09
Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One (2013) 2.06
The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis (2013) 1.99
Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology (2008) 1.93
Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci U S A (2013) 1.93
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis (2013) 1.65
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio (2013) 1.61
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis (2013) 1.61
Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol (2005) 1.57
Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat (2013) 1.55
Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol (2003) 1.50
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (2015) 1.48
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res (2014) 1.35
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill (2011) 1.30
Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill (2011) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction (2009) 1.27
Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol (2010) 1.26
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology (2013) 1.24
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS One (2011) 1.20
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One (2014) 1.16
Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol (1994) 1.15
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis (2012) 1.14
Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res (2014) 1.14
Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis (2002) 1.12
Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis (2004) 1.10
Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol (2007) 1.10
Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat (2006) 1.08
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology (2012) 1.07
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One (2012) 1.07
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol (2006) 1.06
Changing HCV genotypes distribution in Poland--relation to source and time of infection. J Clin Virol (2008) 1.04
Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol (2014) 1.04
Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend (2013) 1.03
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol (2015) 1.02
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol (2014) 1.02
Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece. Am J Public Health (2015) 1.01
Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significance. World J Gastroenterol (2007) 0.97
Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol (1997) 0.97
Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology (2014) 0.92
Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology (2014) 0.91
High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One (2012) 0.91
Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis (2012) 0.90
Hepatitis C virus genotype 4d in Southern Italy: reconstruction of its origin and spread by a phylodynamic analysis. J Med Virol (2012) 0.90
Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol (2011) 0.90
Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int (2014) 0.90
Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med (2013) 0.89
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther (2013) 0.88
Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol (2009) 0.88
Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis (2014) 0.86
Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG and Subtype F1 Strains. AIDS Res Hum Retroviruses (2014) 0.86
Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis (2009) 0.85
Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol (2012) 0.85
[Prevalence and genotype distribution changes in hepatitis C virus co-infection among human immunodeficiency virus-infected patients]. Enferm Infecc Microbiol Clin (2014) 0.84
Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav (2011) 0.84
Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol (2014) 0.84
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol (2014) 0.83
Hepatitis C genotype analysis: results in a large veteran population with review of the implications for clinical practice. Ann Clin Lab Sci (2012) 0.82
Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat (2011) 0.82
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. J Med Virol (2011) 0.81
Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. Infection (2012) 0.81
Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol (2015) 0.80